Latest Research
All publications from the Cancer3.AI database, newest first.
Radiotherapy for Meningiomas: Molecular, Imaging, and Therapeutic Advances.
Eckelmann B, et al
This review article examines the rapidly evolving field of meningioma treatment, integrating recent advances in molecular classification, functional imaging with DOTATATE-PET, and modern radiotherapy delivery techniques. Researchers found that molecular profiling of meningiomas provides important prognostic information that goes beyond the traditional WHO tumor grading system, enabling more precise individual risk stratification for patients. DOTATATE-PET imaging has proven especially valuable for accurately mapping tumor boundaries and identifying biologically active regions, with direct implications for how radiation treatment fields are planned. Clinical study data indicate that dose escalation strategies and PET-guided radiation planning can improve local tumor control, particularly in aggressive or recurrent cases. These findings collectively mark a transition toward precision radiotherapy for meningiomas, where molecular biomarkers and advanced imaging are combined to personalize treatment and potentially improve long-term outcomes for patients with high-risk disease.
Current oncology reports
Source →KMT2B induces the H3K4 trimethylation of RBBP6 promoter to enhance the 131I sensitivity in thyroid carcinoma by restraining STAT1/DPP4 axis.
Wang M, et al
Researchers investigated the molecular mechanisms driving resistance to radioactive iodine (131I) therapy in thyroid carcinoma, a treatment widely used for this cancer type but increasingly limited by acquired resistance. The study found that a protein called DPP4 is abnormally elevated in 131I-resistant thyroid cancer cells, and that reducing DPP4 levels restores sensitivity to radioactive iodine treatment. The enzyme KMT2B was shown to counteract this resistance by adding a chemical mark called H3K4 trimethylation to the promoter region of the RBBP6 gene, which boosts RBBP6 production; elevated RBBP6 then flags the transcription factor STAT1 for degradation via ubiquitination, thereby cutting off the signal that drives DPP4 overexpression. Experiments confirmed that artificially increasing DPP4 neutralized the cancer-suppressing effects of RBBP6 and KMT2B overexpression, validating the linear KMT2B–RBBP6–STAT1–DPP4 molecular axis. These findings identify a novel epigenetic pathway whose manipulation could help restore radioactive iodine sensitivity in patients with resistant thyroid carcinoma, opening avenues for targeted combination therapies.
Epigenomics
Source →Experience and satisfaction towards palliative care in an Ethiopian tertiary care setting: A mixed methods study of patients with cancer and caregivers.
Fentie AM, et al
A mixed-methods study conducted at Tikur Anbessa Specialized Hospital in Ethiopia assessed palliative care satisfaction and lived experiences among 844 cancer patients and their family caregivers between May and August 2024. The overall mean patient satisfaction with palliative care was only 56.7%, indicating widespread dissatisfaction with the quality of services available. Patients residing outside of Addis Ababa, those experiencing moderate to severe pain, and those diagnosed with cancers of the reproductive system, head and neck, lungs, and gastrointestinal tract reported significantly lower satisfaction scores compared to breast cancer patients. Qualitative interviews with 11 patients and 8 caregivers identified major systemic barriers, including lack of holistic patient care, financial hardship, limited access to pain medications, poor coordination and continuity of care, and inadequate hospital infrastructure. These findings highlight a critical gap in palliative care delivery in Ethiopia and call for urgent policy action to integrate palliative services into primary healthcare, expand access to pain management, and address the structural and financial obstacles that prevent patients from receiving dignified, comprehensive end-of-life care.
PLOS global public health
Source →Signals in space: TGF-β defines where and what gut macrophages become.
Blériot C, et al
A new commentary in the Journal of Experimental Medicine highlights groundbreaking research by Jayaraman and colleagues revealing how a signaling molecule called TGF-β (transforming growth factor beta) controls the identity, function, and physical location of long-lived macrophages in the intestine. Macrophages are key immune cells whose behavior is profoundly shaped by the specific tissue environment, or niche, in which they reside. The study demonstrates that TGF-β signaling is not merely supportive but essential for sustaining the specialized characteristics and spatial organization of gut macrophages over time. This discovery clarifies a fundamental mechanism by which the intestinal environment instructs immune cells to adopt and maintain their tissue-specific roles. For patients with gut-related inflammatory and malignant conditions, including inflammatory bowel disease and colorectal cancer, these findings open potential new avenues for therapies that target the intestinal immune microenvironment.
The Journal of experimental medicine
Source →Shared Decision-Making in IPMN of the Pancreas: A Framework for Surgical Decisions Under Uncertainty.
Sacks GD, et al
Researchers conducted a narrative review examining how surgeons and patients navigate treatment decisions for intraductal papillary mucinous neoplasms (IPMNs), pancreatic cysts that carry an uncertain risk of progressing to cancer. The study found that current diagnostic tools cannot reliably distinguish which IPMNs harbor high-grade dysplasia or invasive cancer, leading to substantial variation in surgical recommendations even among patients with similar clinical profiles. Both surgeons and patients interpret malignancy risk, operative burden, and acceptable intervention thresholds very differently, causing some patients to undergo unnecessary major pancreatic surgery while others may be observed until disease progresses. Shared decision-making (SDM) — a structured process that integrates individualized risk estimates, treatment trade-offs, and patient values — was identified as a practical framework to improve decision quality in this uncertainty-laden clinical setting. The authors conclude that embedding SDM into routine IPMN care could reduce unwarranted variation in management, enhance transparency in risk communication, and better align treatment choices with what individual patients actually prioritize.
Annals of surgical oncology
Source →